ReviewAAPS PharmSciTech2025
Sericin from Bombyx Mori as a By-product for DLP 3D Printing in Pharmaceutical and Biomedical Applications.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antioxidant and immunomodulatory activities of sericin and its applications in tumor prevention and treatment.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sericin, a silk-derived protein, has emerged as a potential material for Digital Light Processing (DLP) printing, particularly in uses requiring biocompatibility and sustainability. Sericin is a candidate for developing durable and precise 3D-printed structures due to its natural origin and intrinsic properties like film-forming ability and cross-linking potential. Its biocompatibility makes it suitable for medical applications, such as targeted delivery of anticancer drugs or creation of therapeutic supports directly on affected skin, orthodontic and cosmetic biomaterials, disease modulation, wound healing, antioxidant and antimicrobial applications, and regenerative medicine. Additionally, sericin can strengthen and stabilize printed structures while maintaining environmental integrity, aligning with the growing demand for eco-friendly materials in advanced manufacturing. However, formulating sericin-based resins for DLP printing presents challenges, including optimizing cross-linking and curing processes for obtaining desired properties of material. Overcoming these challenges could unlock the full potential of sericin in diverse fields, such as tissue engineering, where biocompatibility and precise structural integrity are critical. This review investigates the potential of sericin-based resins for 3D printing, emphasizing the protein's compatibility with photopolymerizable systems and its capacity to improve the overall performance of DLP-printed materials. Further research is essential to refine sericin-based formulations, enabling their broader application in 3D printing technologies. By examining the unique characteristics of sericin, including its origins and material properties, this review underscores the protein's potential to drive innovation in sustainable manufacturing. Ultimately, sericin offers a viable alternative to synthetic resins and holds promise for advancing both biomedical and environmental applications through innovative 3D printing technologies.
Indexed as
Identifiers
40246786What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.